Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer’s pharma sales surged in the second quarter, driven by heart drug Xarelto, new ophthalmic Eylea and cancer treatment Stivarga, prompting the German blue chip to raise its sales forecast for medicines this year and assert that its new oral anticoagulant probably will become profitable in 2014.

You may also be interested in...



Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division

Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.

Daiichi Sankyo’s Edoxaban Could Find Role In Treating Sickest Patients

Firm’s Factor Xa inhibitor demonstrates equal efficacy to warfarin with lower overall clinically relevant bleeding in a Phase III study; drug works well even in patients with right ventricular dysfunction, a sign of more serious pulmonary embolism.

Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival

Bayer built upon approvals in the U.S., Europe and Japan to launch Stivarga for the first time in Southeast Asia. Well-established cancer treatment centers in Singapore and Malaysia attract patients in the region as well as far afield from the Middle East.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel